In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in this blog.
There appears to be updated data on Entrectinib (RXDX-101) and TSR -011. Specifically for RXDX-101, 67 patients have been tested, and among 17 inhibitor (not just ALK) naive patients (10/11) 91% treated at or above 400 mg/m2 achieved an objective response rate with durable responses up to 16 cycles (a cycle appears to be 4 weeks so that would be a durable response up to 64 weeks).
Specifically for TSR-011, 69 patients were tested and 46 ALK+ NSCLC patients were reported. For total daily doses at or above 120 mg, 3/5 (60%) ALK inhibitor naive patients responded and 3/6 (50%) patients who had progressed on Crizotinib responded. Unclear if a “response” is an objective response only or includes stable responses.